Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human DS-6000a study in advanced renal cell carcinoma and ovarian tumors
jRCT2031220075Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of raludotatug deruxtecan in renal cell carcinoma (RCC) and Oophoroma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants reporting treatment-emergent adverse events, serious adverse events, and adverse events of special interest and 1 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
renal cell carcinoma (RCC)Oophoroma
Beyond the preview
Go deeper on jRCT2031220075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220075.